Skip to main content

Table 4 Probability of pharmacodynamic target attainment

From: Evaluation of sulfobutylether-β-cyclodextrin (SBECD) accumulation and voriconazole pharmacokinetics in critically ill patients undergoing continuous renal replacement therapy

   C. albicans C. glabrata C. krusei C. parapsilosis C. tropicalis A. fumigatus A. niger A. terreus
Pfizer          
4 mg/kg q12h fAUC/MIC >25 99.9 86.3 97.9 99.5 99.6 97.1   
  fAUC/MIC >35 99.8 81.6 94.8 99.2 99.3 92.8   
6 mg/kg q12h fAUC/MIC >25 99.9 90.0 99.1 99.7 99.8 99.2   
  fAUC/MIC >35 99.8 86.8 98.3 99.6 99.6 97.9   
EUCAST          
4 mg/kg q12h fAUC/MIC >25 99.2      90.3 77.2 60.5
fAUC/MIC >35 99.1      80.3 61.9 41.6
6 mg/kg q12h fAUC/MIC >25 99.4      96.3 91.7 81.4
fAUC/MIC >35 99.2      92.1 80.3 65.4
8 mg/kg q12h fAUC/MIC >25        96.4 89.5
fAUC/MIC >35        90.6 79.0
10 mg/kg q12h fAUC/MIC >25        98.6 94.1
fAUC/MIC >35        95.4 86.1
12 mg/kg q12h fAUC/MIC >25         96.6
fAUC/MIC >35         90.6
CLSI          
4 mg/kg q12h fAUC/MIC >25 99.1 89.1 94.1 99.6 98.0    
fAUC/MIC >35 99.0 86.0 88.1 99.3 97.7    
6 mg/kg q12h fAUC/MIC >25 99.6 92.9 98.0 99.7 98.0    
fAUC/MIC >35 99.5 89.9 95.3 99.6 97.9    
  1. Data reported as % of patients obtaining target fAUC/MIC ratio at the prescribed dose. Data not available for every organism within all databases. fAUC0-12, free area under the concentration-time curve from 0 to 12 hours; MIC, minimum inhibitory concentration; EUCAST, European Committee on Antimicrobial Susceptibility Testing; CLSI, Clinical and Laboratory Standards Institute.